Korea Readying Itself For New Era Of Digital Therapeutics
Pivotal Trials Underway But Reimbursement Lacking
Scrip takes a look at the current landscape in the South Korean digital therapeutics sector, where some remaining gaps in regulation and reimbursement are seen but multiple products are now progressing through pivotal local clinical trials.
You may also be interested in...
Korea’s Key Words For 2023: Regulatory Innovation, Digital Healthcare
The Pink Sheet’s roundup of key regulatory issues in Korea for 2022 and outlook for this year.
Kanaph CEO On Surviving The Biotech Funding 'Barley Hump'
The CEO of Korean bioventure Kanaph Therapeutics, Byoung Chul Lee, talks to Scrip about the difficulties such companies are going through amid generally weak investor sentiment, as well as the company's own financing and R&D plans.
Emocog Setting The Standard For Cognitive Decline DTx in Korea
In a little over two years, the Korean bio-digital healthcare platform company Emocog has moved its digital therapeutic for mild cognitive impairment into pivotal clinical trials and is discussing possible collaborations with big pharma firms, CEO Yoo Hun Noh tells Scrip.